NCT01695876View on ClinicalTrials.gov

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food Effect of AMG 357 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

September 30, 2014

Study Completion Date

October 31, 2014

Conditions
Inflammatory Disease
Interventions
DRUG

AMG 357

Oral administration available in varying dose strength.

DRUG

Placebo

Matching placebo to AMG 357 containing no active drug

Trial Locations (3)

1010

Research Site, Grafton, Auckland

8011

Research Site, Christchurch

Unknown

Christchurch

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT01695876 - A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food Effect of AMG 357 in Healthy Subjects | Biotech Hunter | Biotech Hunter